Development and Validation of an ADA-Tolerant Assay for Quantification of an Exatecan-Based ADC in Monkey Plasma

Yimin Tao,Wei Lu,Jinli Gao,Shuangshuang Yang,Chaoyi Ruan,Yingying Hou,Jing Lu,Junjiu Xu,Jianjian Zhang,Stephanie Pasas-Farmer,Qiuping Qin,Likun Gong

DOI: https://doi.org/10.3390/molecules29030572

IF: 4.6

2024-01-24

Molecules

Abstract:Background: The development of an anti-drug antibody (ADA)-tolerant pharmacokinetic (PK) assay is important when the drug exposure is irrelevant to toxicity in the presence of ADA. We aimed to develop and validate an ADA-tolerant assay for an exatecan-based antibody–drug conjugate (ADC) in monkey plasma. Results: The assay tolerated 5.00 μg/mL of ADA at 12 μg/mL of ADC. Its accuracy and precision results satisfied the acceptance criteria. Furthermore, the assay was free from hook and matrix effects and exhibited good dilutional linearity. Additionally, the ADC in plasma samples was stable under different storage conditions. Method: An ADA-tolerant ADC assay was configured with an anti-payload antibody for capture, and a drug-target protein combined with a horseradish peroxidase (HRP)-labeled antibody against a drug-target-protein tag for detection. Samples were firstly acidified to dissociate drug and ADA complexes, and to convert the carboxylate form to the lactone form of exatecan molecules; then, the ADAs in the samples were removed with a naked antibody-coated microplate. The treated samples were further incubated with coated anti-payload antibody and captured ADC molecules were quantified by the detection reagent. The developed assay was optimized and validated against regulatory guidelines. Conclusions: The assay met both methodological and sample-related ADA tolerance requirements, and was applicable to a nonclinical study in cynomolgus monkeys.

chemistry, multidisciplinary,biochemistry & molecular biology

What problem does this paper attempt to address?

This paper aims to develop and validate an anti - drug antibody (ADA) - tolerant analytical method for quantifying exatecan - based antibody - drug conjugates (ADCs) in monkey plasma. Specifically, the study addresses the following issues:

1. **Develop an ADA - tolerant pharmacokinetic (PK) analysis method**: When ADA is present, drug exposure is not related to toxicity. Therefore, a PK analysis method that can tolerate ADA interference needs to be developed to ensure accurate measurement of ADC concentrations.

2. **Overcome the impact of DAR (drug - antibody ratio) changes**: ADCs may be metabolized and decomposed in vivo, leading to changes in DAR. By selecting appropriate capture and detection reagents, the study developed a method that is insensitive to DAR to reduce the impact of DAR changes on the analysis results.

3. **Handle two forms of exatecan molecules**: Exatecan molecules can exist in carboxylate and lactone forms under different pH conditions, which may lead to differences in the molecular proportions in different samples and thus affect the quantitative results of ADCs. Through an acid pretreatment step, the study converted the carboxylate form of exatecan into the lactone form, ensuring the accuracy of the analysis results.

4. **Remove ADA interference**: By using microplates coated with naked antibodies, the study effectively removed ADA from the samples and avoided ADA interference with the analysis results.

In summary, the main purpose of this paper is to develop an analytical method that can accurately quantify exatecan - based ADCs in the presence of ADA and ensure its reliability and applicability through strict validation.